Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Hansmann

Showing results (221-230 of 259) with videos related to

Pageof 26
Sort By:
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2016
miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's diseaseSylvia Hartmann, Claudia Döring, Claudio Agostinelli, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Hemasphere|March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLAKatrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Blood|November 8, 2019
Localized- and advanced-stage follicular lymphomas differ in their gene expression profilesAnnette M Staiger, Eva Hoster, Vindi Jurinovic, et al.
Haematologica|November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsHeinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Cancer Immunology Research|September 19, 2022
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple MyelomaCarlotta Welters, María Fernanda Lammoglia Cobo, Christian Alexander Stein, et al.
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Pageof 26

Showing results (221-230 of 259) with videos related to

Sort By:
Pageof 26
International Journal of Cancer|June 15, 2017
TP53 mutation and survival in aggressive B cell lymphomaThorsten Zenz, Markus Kreuz, Maxi Fuge, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2016
miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's diseaseSylvia Hartmann, Claudia Döring, Claudio Agostinelli, et al.
Haematologica|May 9, 2020
Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPPRon Daniel Jachimowicz, Luise Pieper, Sarah Reinke, et al.
Blood|August 22, 2018
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profilesJohannes C Hellmuth, Abner Louissaint, Monika Szczepanowski, et al.
Hemasphere|March 10, 2025
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLAKatrin S Kurz, Sophia Steinlein, Markus Kreuz, et al.
Blood|November 8, 2019
Localized- and advanced-stage follicular lymphomas differ in their gene expression profilesAnnette M Staiger, Eva Hoster, Vindi Jurinovic, et al.
Haematologica|November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsHeinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Cancer Immunology Research|September 19, 2022
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple MyelomaCarlotta Welters, María Fernanda Lammoglia Cobo, Christian Alexander Stein, et al.
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
Pageof 26